Home › Linfoma di Burkitt › New York

Studi clinici su Linfoma di Burkitt nello stato di New York

20 studi su Linfoma di Burkitt cercano partecipanti presso sedi nello stato di New York.

Città nello stato di New York

Testo ufficiale dello studio (inglese)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Albany Medical Center, Albany
Roswell Park Cancer Institute, Buffalo
NYU Langone Hospital - Long Island, Mineola
e altri 9

In reclutamentoFase 2

366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Roswell Park Cancer Institute, Buffalo
Northwell Health/Center for Advanced Medicine, Lake Success
North Shore University Hospital, Manhasset
e altri 4

In reclutamentoFase 3

Età da 18 a 39 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Northwell Health/Center for Advanced Medicine, Lake Success
North Shore University Hospital, Manhasset
Long Island Jewish Medical Center, New Hyde Park
e altri 2

In reclutamentoFase 2

Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Albany Medical Center, Albany
Roswell Park Cancer Institute, Buffalo
The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
e altri 7

In reclutamentoFase 2

365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

David H. Koch Center for Cancer Care, New York
Montefiore Medical Center PRIME, The Bronx

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center, New York

In reclutamentoFase 3

Età 1 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07223021

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Memorial Sloan Kettering Cancer Center ( Site 1010), New York
New York Medical College ( Site 1023), Valhalla

In reclutamentoFase 1/2

6 Months – 25 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06395103

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

The Mount Sinai Hospital, New York

In reclutamentoFase 1

Età da 0 a 18 · Tutti i sessi · Aggiornato il 16 set 2026 · NCT06173518

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
NYU Langone Hospital - Long Island, Mineola
e altri 7

In reclutamentoFase 2

Età da 1 a 30 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
Roswell Park Cancer Institute, Buffalo
e altri 12

In reclutamentoFase 3

365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, New York

In reclutamentoFase 1/2

Età 12 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT06137118

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

New York Medical College, Valhalla

In reclutamentoFase 1/2

Età da 13 a 90 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06533579

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

New York Medical Center, Valhalla

In reclutamentoFase 1/2

Età da 12 a 70 · Tutti i sessi · Aggiornato il 15 apr 2026 · NCT04491370

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Memorial Sloan Kettering Cancer Center, New York

In reclutamentoFase 2

Età da 18 a 54 · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06918431

Study of SGR-1505 in Mature B-Cell Neoplasms

Roswell Park Comprehensive Cancer Center, Buffalo
Weill Cornell, New York
Montefiore Medical Center, The Bronx

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT05544019

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Roswell Park Comprehensive Cancer Center, Buffalo

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 4 nov 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Roswell Park Comprehensive Cancer Center, Buffalo
Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

In reclutamentoFase 1/2

Età da 15 a 50 · Tutti i sessi · Aggiornato il 9 set 2025 · NCT04150497

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

New York Medical College, Valhalla

In reclutamentoFase 2

Età da 3 a 31 · Tutti i sessi · Aggiornato il 8 ago 2025 · NCT02393157

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Roswell Park Cancer Institute, Buffalo

In reclutamentoFase 2

Età da 1 a 25 · Tutti i sessi · Aggiornato il 4 mag 2025 · NCT03509961

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.